Pfizer Inc.

PFE · CIK 0000078003

19 fiscal years · 68 SEC filings · every number carries its receipt

Revenue (FY)

$62.58B1.6%

FY2025

Net income (FY)

$7.77B3.2%

FY2025

Free cash flow (FY)

$9.07B7.7%

FY2025

Diluted EPS (FY)

$1.363.5%

FY2025

The story, charted

The shape of the business

FY2007–FY2025 · hover any year for its receipt

Revenue & net incomeRevenueNet income

revenue 1.3× since FY2007 · net margin 16.8% → 12.4%

MarginsNet marginFCF margin

FY2025: net 12.4% · free cash flow 14.5% of revenue

Cash engineOperating cash flowFree cash flow

FY2025: $11.70B operating cash − $2.63B capex = $9.07B free cash flow

Returns on capitalReturn on equityReturn on assets

return on equity 14% (FY2008) → 9% (FY2025) · on assets 3.7%

Balance sheetLiabilitiesEquity

FY2025: $208.16B assets · $121.39B liabilities · $86.48B equity

The receipts

Financial statements

Annual Quarterly (as reported)

USD in millions except per-share and share counts. Every value links to the filing it came from — hover for the us-gaap tag, click for the 10-K/10-Q on sec.gov.

USD millions	Q1 2026	Q3 2025	Q2 2025	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022	Q2 2022
Revenue	14,451	16,654	14,653	13,715	17,702	13,283	14,879	13,491	13,007	18,486	22,638	27,742
Net income	2,687	3,541	2,910	2,967	4,465	41	3,115	(2,382)	2,327	5,543	8,608	9,906
Diluted EPS	0.47	0.62	0.51	0.52	0.78	0.01	0.55	(0.42)	0.41	0.97	1.51	1.73
Diluted shares	5,731	5,714	5,706	5,710	5,705	5,696	5,697	5,646	5,713	5,727	5,718	5,712
Operating cash flow	2,615	—	—	2,335	—	—	1,090	—	—	1,212	—	—
Capital expenditures	436	—	—	564	—	—	704	—	—	1,139	—	—
Free cash flow	2,179	—	—	1,771	—	—	386	—	—	73	—	—
Cash & equivalents	1,703	1,343	1,638	1,430	1,092	1,052	719	3,148	2,632	2,166	1,298	1,780
Total assets	207,618	208,731	206,095	208,028	219,476	216,193	221,095	215,021	220,168	195,617	195,350	195,290
Total liabilities	117,214	115,635	117,083	117,391	126,918	128,218	128,537	117,817	120,875	94,381	102,459	107,821
Shareholders' equity	90,101	92,801	88,695	90,338	92,286	87,700	92,282	96,934	99,019	100,970	92,631	87,208

Figures as reported in SEC filings, normalized by stonks with the tag mapping shown on hover; missing tags render as “—”, never as zero. Free cash flow is derived (operating cash flow − capex) with both parents recorded in its lineage. Quarterly view shows as-reported 10-Q periods; Q4 synthesis ships in Phase 1. See methodology.